Department of Biochemistry, Medical University of Lodz, Lodz, Poland.
Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland.
J Physiol Pharmacol. 2021 Oct;72(5). doi: 10.26402/jpp.2021.5.01. Epub 2022 Feb 12.
Inflammatory bowel disease (IBD), including the two main subtypes - Crohn's disease (CD) and ulcerative colitis (UC) - has a wide range of extra-intestinal manifestations (EIMs) that are major causes of morbidity and disability. The following EIMs can be classified as IBD-associated: mucocutaneous, ocular, pulmonary, renal, genitourinary, hematological, neurological, psychiatric, cardiac and hepatobiliary. The latter include primary sclerosing cholangitis (PSC), cholelithiasis, IgG4 associated cholangiopathy (IAC), autoimmune hepatitis (AIH), non-alcoholic fatty liver disease (NAFLD), hepatitis B and C, and drug-induced hepatotoxicity. The aim of this review is to examine our current knowledge of IBD - associated hepatobiliary EIMs and their treatment.
炎症性肠病（IBD），包括两种主要亚型——克罗恩病（CD）和溃疡性结肠炎（UC）——有广泛的肠外表现（EIMs），这些表现是发病率和残疾的主要原因。以下 EIMs 可归类为与 IBD 相关：黏膜皮肤、眼部、肺部、肾脏、泌尿生殖、血液、神经、精神、心脏和肝胆。后者包括原发性硬化性胆管炎（PSC）、胆石症、IgG4 相关胆管病（IAC）、自身免疫性肝炎（AIH）、非酒精性脂肪性肝病（NAFLD）、乙型肝炎和丙型肝炎，以及药物性肝毒性。本文的目的是探讨我们目前对与 IBD 相关的肝胆肠外表现及其治疗的认识。
